| BCBS Federal Medical & Drug | 2.04.62 Multimarker Serum Testing Related to Ovarian Cancer | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.79 Genetic Testing for Alpha-1 Antitrypsin Deficiency | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.83 Genetic Testing for FMR1 Variants (Including Fragile X Syndrome) | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.84 Measurement of Serum Antibodies to Selected Biologic Agents | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.89 Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.95 Human Leukocyte Antigen Testing for Celiac Disease | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.96 Genetic Testing for Statin-Induced Myopathy | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.98 Drug Testing in Pain Management and Substance Use Disorder Treatment | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.102 Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.111 Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management | 2026-03-01 |